Hematology News and Research

RSS

Hematology, also spelled haematology, is the branch of biology (physiology), pathology, clinical laboratory, internal medicine, and pediatrics that is concerned with the study of blood, the blood-forming organs, and blood diseases. Hematology includes the study of etiology, diagnosis, treatment, prognosis, and prevention of blood diseases.

HOC pleads guilty for selling misbranded, unapproved chemotherapy drugs

Hematology and Oncology Center (HOC) PLLC of Somerset, Kentucky has pleaded guilty to federal charges that the firm purchased and sold unapproved and improperly labeled chemotherapy drugs.

27 Jun 2014

Mode of cancer cell recognition opens up new possibilities for leukaemia immunotherapy

Scientists at A*STAR's Singapore Immunology Network (SIgN) have discovered a new class of lipids in the leukaemia cells that are detected by a unique group of immune cells. By recognising the lipids, the immune cells stimulate an immune response to destroy the leukaemia cells and suppress their growth.

25 Jun 2014

Ligand Pharmaceuticals, TG Therapeutics sign global license agreement for IRAK-4 inhibitors

Ligand Pharmaceuticals Incorporated announced the signing of an exclusive global license agreement with TG Therapeutics, Inc. for the development and commercialization of Ligand's Interleukin-1 Receptor Associated Kinase-4 (IRAK-4) inhibitors.

24 Jun 2014

Physician describes ways to combat post-cancer pain

More and more people are surviving their cancer. Unfortunately, sometimes survival can come with pain. Although many people won't feel any pain after their cancer treatment, some may have chronic, bothersome pain.

23 Jun 2014

Clinical trial shows that selumetinib drug can delay progression of metastatic uveal melanoma

For the first time, a therapy has been found that can delay progression of metastatic uveal melanoma, a rare and deadly form of melanoma of the eye.

20 Jun 2014

Research demonstrates association between diversity of gut bacteria and survival

New research, published online today in Blood, the Journal of the American Society of Hematology, suggests that the diversity of bacteria in the gastrointestinal tract of patients receiving stem cell transplants may be an important predictor of their post-transplant survival.

18 Jun 2014

Inovio evaluates responses of immunotherapy product in treating HPV linked head and neck cancer

Inovio Pharmaceuticals, Inc. (NYSE MKT: INO) today announced it has initiated a phase I/IIa clinical trial to evaluate safety, immunogenicity and clinical responses of its immunotherapy product, INO-3112, in treating human papillomavirus (HPV)- associated head and neck cancer.

10 Jun 2014

Findings add surprising new dimension to understanding of antibody repertoires

As elite soldiers of the body's immune response, B cells serve as a vast standing army ready to recognize and destroy invading antigens, including infections and cancer cells. To do so, each new B cell comes equipped with its own highly specialized weapon, a unique antibody protein that selectively binds to specific parts of the antigen.

10 Jun 2014

Actinium's Chairman to discuss role of alpha-particle radiopharmaceuticals at SNMMI Annual Meeting

Actinium Pharmaceuticals, Inc. ("Actinium" or "the Company"), a biopharmaceutical company developing innovative targeted payload immunotherapeutics for the treatment of advanced cancers, today announced that Actinium's Clinical Advisory Board Chairman Joseph Jurcic, MD will participate in an upcoming panel discussion highlighting the role of Actinium's alpha-particle radiopharmaceuticals in the treatment of leukemia patients.

9 Jun 2014

Survival rates for African-Americans with head and neck cancer not improved in the last 40 years

The national survival rates for African-Americans diagnosed with head and neck cancer have not improved in the last 40 years despite advances in the treatment and management of the disease, University of Missouri School of Medicine researchers have found in a new study.

6 Jun 2014

Interim data from Promedior’s PRM-151 Phase 2 myelofibrosis clinical trial to be presented at 19th EHA Congress

Promedior, Inc., a clinical stage biotechnology company developing novel therapeutics for the treatment of fibrosis, today announced that Ruben Mesa, MD, will present interim data from the Company's ongoing Phase 2 clinical trial of its lead product candidate, PRM-151, for the treatment of myelofibrosis, in a poster presentation on June 14, 2014 at the 19th Congress of European Hematology Association (EHA) which is being held in Milan, Italy, from June 12-15, 2014.

5 Jun 2014

Leukemia researcher wins 2014 Taubman Prize for Excellence in Translational Medical Science

A physician-scientist who developed a personalized immunotherapy for leukemia using patients' own T cells is the recipient of the 2014 Taubman Prize for Excellence in Translational Medical Science, awarded by the A. Alfred Taubman Medical Research Institute at the University of Michigan Medical School.

4 Jun 2014

UIC conducts clinical trial to evaluate three-drug combination therapy for advanced pancreatic cancer

Researchers at the University of Illinois at Chicago are conducting a clinical trial to evaluate a new, three-drug combination therapy for advanced pancreatic cancer.

4 Jun 2014

Scientist discovers new path to stop breast cancer cells from invading organs

The primary cause of death from breast cancer is the spread of tumor cells from the breast to other organs in the body. Northwestern Medicine- scientists have discovered a new pathway that can stop breast cancer cells from spreading.

4 Jun 2014

Breast cancer worry, risk behavior higher among teenage girls

Teenage girls with a familial or genetic risk for breast cancer worry more about getting the disease, even when their mother has no history, compared to girls their age with no known high risks, according to new data presented today by researchers from Penn Medicine's Abramson Cancer Center at the annual meeting of the American Society of Clinical Oncology in Chicago (Abstract #9527).

3 Jun 2014

Nonadherence triples relapse risk in African American and Asian children in remission from ALL

An estimated 25 percent of children in remission from acute lymphocytic leukemia (ALL) are missing too many doses of an essential maintenance medication that minimizes their risk of relapse, according to a study published online today in Blood, the Journal of the American Society of Hematology.

3 Jun 2014

Jazz Pharmaceuticals' JZP-110 improves symptoms of EDS in adults with narcolepsy

Jazz Pharmaceuticals plc today presented data from the Phase 2b study evaluating JZP-110 (formerly known as ADX-N05) as a potential new treatment for the symptoms of excessive daytime sleepiness (EDS) in adults with narcolepsy.

3 Jun 2014

P2Y12 and blood clotting: an interview with Dr. Jacobson, NIH

We already understand the many steps involved in blood clotting in great mechanistic detail. The process of blood vessels closing off in response to injury is necessary for preserving life, but blood platelets that are over-active, or activated inappropriately because of unstable plaque, can lead to heart attacks and strokes.

3 Jun 2014

FDA approves Can-Fite's study protocol for CF102 Phase II clinical trial for advanced liver cancer

Can-Fite BioPharma Ltd., a biotechnology company with a pipeline of proprietary small molecule drugs that address inflammatory and cancer diseases, announced today that the U.S. FDA has agreed with the Company's study protocol for its Phase II clinical trial of CF102 for the treatment of advanced liver cancer.

2 Jun 2014

Ibrutinib outperforms ofatumumab as second-line therapy for CLL treatment

In a head-to-head comparison of two Food and Drug Administration-approved drugs for the treatment of relapsed chronic lymphocytic leukemia (CLL), ibrutinib significantly outperformed ofatumumab as a second-line therapy, according to a multicenter interim study published in the OnLine First edition of the New England Journal of Medicine.

2 Jun 2014

Hematology News and Research

Further Reading

HOC pleads guilty for selling misbranded, unapproved chemotherapy drugs

Mode of cancer cell recognition opens up new possibilities for leukaemia immunotherapy

Ligand Pharmaceuticals, TG Therapeutics sign global license agreement for IRAK-4 inhibitors

Physician describes ways to combat post-cancer pain

Clinical trial shows that selumetinib drug can delay progression of metastatic uveal melanoma

Research demonstrates association between diversity of gut bacteria and survival

Inovio evaluates responses of immunotherapy product in treating HPV linked head and neck cancer

Findings add surprising new dimension to understanding of antibody repertoires

Actinium's Chairman to discuss role of alpha-particle radiopharmaceuticals at SNMMI Annual Meeting

Survival rates for African-Americans with head and neck cancer not improved in the last 40 years

Interim data from Promedior’s PRM-151 Phase 2 myelofibrosis clinical trial to be presented at 19th EHA Congress

Leukemia researcher wins 2014 Taubman Prize for Excellence in Translational Medical Science

UIC conducts clinical trial to evaluate three-drug combination therapy for advanced pancreatic cancer

Scientist discovers new path to stop breast cancer cells from invading organs

Breast cancer worry, risk behavior higher among teenage girls

Nonadherence triples relapse risk in African American and Asian children in remission from ALL

Jazz Pharmaceuticals' JZP-110 improves symptoms of EDS in adults with narcolepsy

P2Y12 and blood clotting: an interview with Dr. Jacobson, NIH

FDA approves Can-Fite's study protocol for CF102 Phase II clinical trial for advanced liver cancer

Ibrutinib outperforms ofatumumab as second-line therapy for CLL treatment

Industry Focus eBook - Cell & Gene Therapy (1st Edition) eBook

Latest eBooks

Industry Focus eBook - Analytical Chemistry (3rd edition)

Industry Focus eBook - Microbiome (1st edition)

Industry Focus eBook - Cell biology (5th edition)

Advancing degrader and proximity-based drug development

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Expanding access to NMR with the Fourier 80 Duo